The role of Hypoxia in Glioblastoma radiotherapy resistance

Detalhes bibliográficos
Autor(a) principal: Chédeville, Agathe L.
Data de Publicação: 2021
Outros Autores: Madureira, Patricia
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.1/15166
Resumo: Glioblastoma (GB) (grade IV astrocytoma) is the most malignant type of primary brain tumor with a 16 months median survival time following diagnosis. Despite increasing attention regarding the development of targeted therapies for GB that resulted in around 450 clinical trials currently undergoing, radiotherapy still remains the most clinically effective treatment for these patients. Nevertheless, radiotherapy resistance (radioresistance) is commonly observed in GB patients leading to tumor recurrence and eventually patient death. It is therefore essential to unravel the molecular mechanisms underpinning GB cell radioresistance in order to develop novel strategies and combinational therapies focused on enhancing tumor cell sensitivity to radiotherapy. In this review, we present a comprehensive examination of the current literature regarding the role of hypoxia (O<sub>2</sub> partial pressure less than 10 mmHg), a main GB microenvironmental factor, in radioresistance with the ultimate goal of identifying potential molecular markers and therapeutic targets to overcome this issue in the future.
id RCAP_376b52a2a99630abc63471d37c071ce4
oai_identifier_str oai:sapientia.ualg.pt:10400.1/15166
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling The role of Hypoxia in Glioblastoma radiotherapy resistanceGlioblastoma (GB)HypoxiaRadiotherapyHypoxia Inducible Factor (HIF);RadioresistanceGlioma stem cells (GSC)Glioblastoma (GB) (grade IV astrocytoma) is the most malignant type of primary brain tumor with a 16 months median survival time following diagnosis. Despite increasing attention regarding the development of targeted therapies for GB that resulted in around 450 clinical trials currently undergoing, radiotherapy still remains the most clinically effective treatment for these patients. Nevertheless, radiotherapy resistance (radioresistance) is commonly observed in GB patients leading to tumor recurrence and eventually patient death. It is therefore essential to unravel the molecular mechanisms underpinning GB cell radioresistance in order to develop novel strategies and combinational therapies focused on enhancing tumor cell sensitivity to radiotherapy. In this review, we present a comprehensive examination of the current literature regarding the role of hypoxia (O<sub>2</sub> partial pressure less than 10 mmHg), a main GB microenvironmental factor, in radioresistance with the ultimate goal of identifying potential molecular markers and therapeutic targets to overcome this issue in the future.MDPISapientiaChédeville, Agathe L.Madureira, Patricia2021-03-04T13:21:56Z2021-02-012021-02-05T14:09:58Z2021-02-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.1/15166engCancers 13 (3): 542 (2021)2072-669410.3390/cancers13030542info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-07-24T10:27:26Zoai:sapientia.ualg.pt:10400.1/15166Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T20:05:58.035675Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv The role of Hypoxia in Glioblastoma radiotherapy resistance
title The role of Hypoxia in Glioblastoma radiotherapy resistance
spellingShingle The role of Hypoxia in Glioblastoma radiotherapy resistance
Chédeville, Agathe L.
Glioblastoma (GB)
Hypoxia
Radiotherapy
Hypoxia Inducible Factor (HIF);
Radioresistance
Glioma stem cells (GSC)
title_short The role of Hypoxia in Glioblastoma radiotherapy resistance
title_full The role of Hypoxia in Glioblastoma radiotherapy resistance
title_fullStr The role of Hypoxia in Glioblastoma radiotherapy resistance
title_full_unstemmed The role of Hypoxia in Glioblastoma radiotherapy resistance
title_sort The role of Hypoxia in Glioblastoma radiotherapy resistance
author Chédeville, Agathe L.
author_facet Chédeville, Agathe L.
Madureira, Patricia
author_role author
author2 Madureira, Patricia
author2_role author
dc.contributor.none.fl_str_mv Sapientia
dc.contributor.author.fl_str_mv Chédeville, Agathe L.
Madureira, Patricia
dc.subject.por.fl_str_mv Glioblastoma (GB)
Hypoxia
Radiotherapy
Hypoxia Inducible Factor (HIF);
Radioresistance
Glioma stem cells (GSC)
topic Glioblastoma (GB)
Hypoxia
Radiotherapy
Hypoxia Inducible Factor (HIF);
Radioresistance
Glioma stem cells (GSC)
description Glioblastoma (GB) (grade IV astrocytoma) is the most malignant type of primary brain tumor with a 16 months median survival time following diagnosis. Despite increasing attention regarding the development of targeted therapies for GB that resulted in around 450 clinical trials currently undergoing, radiotherapy still remains the most clinically effective treatment for these patients. Nevertheless, radiotherapy resistance (radioresistance) is commonly observed in GB patients leading to tumor recurrence and eventually patient death. It is therefore essential to unravel the molecular mechanisms underpinning GB cell radioresistance in order to develop novel strategies and combinational therapies focused on enhancing tumor cell sensitivity to radiotherapy. In this review, we present a comprehensive examination of the current literature regarding the role of hypoxia (O<sub>2</sub> partial pressure less than 10 mmHg), a main GB microenvironmental factor, in radioresistance with the ultimate goal of identifying potential molecular markers and therapeutic targets to overcome this issue in the future.
publishDate 2021
dc.date.none.fl_str_mv 2021-03-04T13:21:56Z
2021-02-01
2021-02-05T14:09:58Z
2021-02-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.1/15166
url http://hdl.handle.net/10400.1/15166
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Cancers 13 (3): 542 (2021)
2072-6694
10.3390/cancers13030542
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799133299859259392

Registros relacionados